| 1. |
濮天, 方強, 陳子祥, 等. 肝內膽管癌發病機制及治療相關進展. 中華消化外科雜志, 2020, 19(6): 697-702.
|
| 2. |
高博, 趙海鷹. 肝內膽管癌的流行病學特征及危險因素研究進展. 現代腫瘤醫學, 2020, 28(7): 1214-1217.
|
| 3. |
畢超, 王黎明, 安松林, 等. 123例肝內膽管癌患者手術切除后的生存分析. 中華腫瘤雜志, 2016, 38(6): 466-471.
|
| 4. |
敖建陽, 程慶保, 劉辰, 等. 肝內膽管癌的治療難點及應對策略. 肝膽胰外科雜志, 2020, 32(6): 321-325.
|
| 5. |
Reich M, Deutschmann K, Sommerfeld A, et al. TGR5 is essential for bile acid-dependent cholangiocyte proliferation in vivo and in vitro. Gut, 2016, 65(3): 487-501.
|
| 6. |
Li ZY, Zhou JJ, Luo CL, et al. Activation of TGR5 alleviates inflammation in rheumatoid arthritis peripheral blood mononuclear cells and in mice with collagen Ⅱ-induced arthritis. Mol Med Rep, 2019, 20(5): 4540-4550.
|
| 7. |
巢佳燈, 秦錫虎. 膽汁酸G蛋白偶聯受體5在消化道疾病中的研究進展. 醫學綜述, 2019, 25(6): 1128-1132.
|
| 8. |
王馨悅, 李楠, 董兵, 等. mortalin蛋白在宮頸鱗癌中的表達及其對腫瘤轉移能力的影響. 中國病理生理雜志, 2020, 36(1): 146-151.
|
| 9. |
Jin H, Ji M, Chen L, et al. The clinicopathological significance of mortalin overexpression in invasive ductal carcinoma of breast. J Exp Clin Cancer Res, 2016, 35(1): 42-51.
|
| 10. |
Li AD, Xie XL, Qi W, et al. TGR5 promotes cholangiocarcinoma by interacting with mortalin. Exp Cell Res, 2020, 389(2): 111855-111860.
|
| 11. |
李增山, 李青. 2010年版消化系統腫瘤WHO分類解讀. 中華病理學雜志, 2011, 40(5): 351-354.
|
| 12. |
許良中, 楊文濤. 免疫組織化學反應結果的判斷標準. 中國癌癥雜志, 1996, 6(4): 229-231.
|
| 13. |
Clements O, Eliahoo J, Kim JU, et al. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: A systematic review and meta-analysis. J Hepatol, 2020, 72(1): 95-103.
|
| 14. |
傅俊, 李俊, 項紅軍, 等. 肝切除切緣的距離對肝內膽管癌伴乙型肝炎肝硬化預后的影響. 肝膽外科雜志, 2017, 25(2): 89-94.
|
| 15. |
李永勝, 孫保君. 肝內膽管癌手術治療的預后影響因素分析. 實用癌癥雜志, 2016, 31(4): 610-612.
|
| 16. |
van Nierop FS, Scheltema MJ, Eggink HM, et al. Clinical relevance of the bile acid receptor TGR5 in metabolism. Lancet Diabetes Endocrinol, 2017, 5(3): 224-233.
|
| 17. |
Keitel V, Stindt J, H?ussinger D. Bile acid-activated receptors: GPBAR1 (TGR5) and other G protein-coupled receptors. Handb Exp Pharmacol, 2019, 256(1): 19-49.
|
| 18. |
Ma K, Tang D, Yu C, et al. Progress in research on the roles of TGR5 receptor in liver diseases. Scand J Gastroenterol, 2021, 56(6): 717-726.
|
| 19. |
Carino A, Graziosi L, D'Amore C, et al. The bile acid receptor GPBAR1 (TGR5) is expressed in human gastric cancers and promotes epithelial-mesenchymal transition in gastric cancer cell lines. Oncotarget, 2016, 7(38): 61021-61035.
|
| 20. |
金海丹, 周憲春, 張松男, 等. Mortalin促進人乳腺癌細胞MDA-MB231的惡性進展. 基礎醫學與臨床, 2015, 35(6): 833-835.
|
| 21. |
Wu PK, Hong SK, Starenki D, et al. Mortalin/HSPA9 targeting selectively induces KRAS tumor cell death by perturbing mitochondrial membrane permeability. Oncogene, 2020, 39(21): 4257-4270.
|
| 22. |
Kiraly VTR, Dores-Silva PR, Serr?o VHB, et al. Thermal aggregates of human mortalin and Hsp70-1A behave as supramolecular assemblies. Int J Biol Macromol, 2020, 146(1): 320-331.
|
| 23. |
Wadhwa R, Ryu J, Ahn HM, et al. Functional significance of point mutations in stress chaperone mortalin and their relevance to Parkinson disease. J Biol Chem, 2015, 290(13): 8447-8456.
|
| 24. |
Yun CO, Bhargava P, Na Y, et al. Relevance of mortalin to cancer cell stemness and cancer therapy. Sci Rep, 2017, 7(1): 42016-42019.
|
| 25. |
Xu M, Zhang Y, Cui M, et al. Mortalin contributes to colorectal cancer by promoting proliferation and epithelial–mesenchymal transition. IUBMB Life, 2020, 72(4): 771-781.
|
| 26. |
陳靜, 李建生, 劉文斌, 等. Mortalin在肝癌中的表達及其與血管生成和上皮間質轉化的關系. 安徽醫科大學學報, 2014, 49(6): 795-799.
|